Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue.

AUTOR(ES)

Patchett, A A

RESUMO

A potent, orally active growth hormone (GH) secretagogue L-163,191 belonging to a recently synthesized structural class has been characterized. L-163,191 releases GH from rat pituitary cells in culture with EC50 = 1.3 +/- 0.09 nM and is mechanistically indistinguishable from the GH-releasing peptide GHRP-6 and the prototypical nonpeptide GH secretagogue L-692,429 but clearly distinguishable from the natural GH secretagogue, GH-releasing hormone. L-163,191 elevates GH in dogs after oral doses as low as 0.125 mg/kg and was shown to be specific in its release of GH without significant effect on plasma levels of aldosterone, luteinizing hormone, thyroxine, and prolactin after oral administration of 1 mg/kg. Only modest increases in cortisol were observed. Based on these properties, L-163,191 has been selected for clinical studies.

Documentos Relacionados

• Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.
• Chemical, biochemical, pharmacokinetic, and biological properties of L-680,833: a potent, orally active monocyclic beta-lactam inhibitor of human polymorphonuclear leukocyte elastase.
• Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone.
• [Phe4]somatostatin: a potent, selective inhibitor of growth hormone release.
• Human monocyte-derived mucus secretagogue.